Login to Your Account

Medivation Rocked by Dimebon Miss in Late-Stage AD Study

By Catherine Hollingsworth

Thursday, March 4, 2010
Shares in Medivation Inc. fell 67.5 percent Wednesday on news that its Phase III trials of Alzheimer's drug candidate Dimebon missed all of the study's stated goals, smashing some high hopes on Wall Street. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription